BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11564090)

  • 41. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.
    Shaughnessy P; Alexander W; Tran H; Ririe D; Splichal J; Pollack M; Bachier C; LeMaistre C
    Mil Med; 2006 Feb; 171(2):161-5. PubMed ID: 16578989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
    Ferrara F; Mele G; Palmieri S; Pedata M; Copia C; Riccardi C; Izzo T; Criscuolo C; Musto P
    Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
    Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
    Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
    Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
    Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
    Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
    J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
    Cappelli B; Chiesa R; Evangelio C; Biffi A; Roccia T; Frugnoli I; Biral E; Noè A; Fossati M; Finizio V; Miniero R; Napolitano S; Ferrua F; Soliman C; Ciceri F; Roncarolo MG; Marktel S
    Br J Haematol; 2009 Nov; 147(4):554-60. PubMed ID: 19747363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
    Kangarloo SB; Naveed F; Ng ES; Chaudhry MA; Wu J; Bahlis NJ; Brown CB; Daly A; Duggan P; Geddes M; Quinlan D; Savoie ML; Shafey M; Stewart DA; Storek J; Yang M; Zacarias N; Yue P; Magliocco AM; Russell JA
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):295-301. PubMed ID: 21801704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
    Zhang H; Graiser M; Hutcherson DA; Dada MO; McMillan S; Ali Z; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1287-94. PubMed ID: 22370160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
    Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L
    Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 54. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model.
    Kang EM; Hsieh MM; Metzger M; Krouse A; Donahue RE; Sadelain M; Tisdale JF
    Exp Hematol; 2006 Feb; 34(2):132-9. PubMed ID: 16459181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
    Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children.
    Krivoy N; Hoffer E; Lurie Y; Bentur Y; Rowe JM
    Curr Drug Saf; 2008 Jan; 3(1):60-6. PubMed ID: 18690982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma.
    Toor AA; Ayers J; Strupeck J; Parthasarathy M; Creech S; Rodriguez T; Stiff PJ
    Br J Haematol; 2004 Mar; 124(6):769-76. PubMed ID: 15009065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.
    Dalle JH; Wall D; Theoret Y; Duval M; Shaw L; Larocque D; Taylor C; Gardiner J; Vachon MF; Champagne MA
    Bone Marrow Transplant; 2003 Oct; 32(7):647-51. PubMed ID: 13130310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.